J.W. Cole Advisors Inc. Raises Stock Holdings in Axon Enterprise, Inc (NASDAQ:AXON)

J.W. Cole Advisors Inc. boosted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 24.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 7,331 shares of the biotechnology company's stock after buying an additional 1,461 shares during the period. J.W. Cole Advisors Inc.'s holdings in Axon Enterprise were worth $3,856,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in Axon Enterprise in the 1st quarter worth approximately $1,110,000. Quotient Wealth Partners LLC purchased a new stake in Axon Enterprise in the 1st quarter worth approximately $438,000. CX Institutional purchased a new position in shares of Axon Enterprise during the 1st quarter valued at approximately $115,000. GAMMA Investing LLC lifted its position in shares of Axon Enterprise by 11.8% during the 1st quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company's stock valued at $765,000 after buying an additional 154 shares in the last quarter. Finally, DAVENPORT & Co LLC lifted its position in shares of Axon Enterprise by 5.1% during the 1st quarter. DAVENPORT & Co LLC now owns 940 shares of the biotechnology company's stock valued at $494,000 after buying an additional 46 shares in the last quarter. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Trading Up 1.4%

NASDAQ:AXON opened at $756.09 on Monday. The firm has a market cap of $58.86 billion, a P/E ratio of 182.63, a PEG ratio of 87.03 and a beta of 1.29. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68. The stock's 50 day simple moving average is $763.54 and its 200-day simple moving average is $646.31. Axon Enterprise, Inc has a 12-month low of $279.02 and a 12-month high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The business had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The company's revenue for the quarter was up 31.3% compared to the same quarter last year. Equities analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Michael Garnreiter sold 5,913 shares of the business's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the sale, the director directly owned 17,740 shares in the company, valued at approximately $13,482,400. The trade was a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Jennifer H. Mak sold 75 shares of the business's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $771.81, for a total value of $57,885.75. Following the sale, the chief accounting officer owned 15,240 shares in the company, valued at approximately $11,762,384.40. The trade was a 0.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,642 shares of company stock valued at $25,090,528 in the last 90 days. 5.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

AXON has been the subject of several recent research reports. The Goldman Sachs Group increased their price objective on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. JPMorgan Chase & Co. raised their target price on Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research note on Thursday. Bank of America raised their price objective on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. Wolfe Research initiated coverage on Axon Enterprise in a research report on Monday, July 7th. They set an "outperform" rating for the company. Finally, Morgan Stanley set a $885.00 price objective on Axon Enterprise and gave the stock an "overweight" rating in a research report on Friday, July 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and an average price target of $763.75.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.